Image

Natural History in Children up to 10 Years With Moderate to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes

Recruiting
- 10 years of age
Both
Phase N/A

Powered by AI

Overview

The purpose of this study is to follow the natural history of non-syndromic hearing loss caused by mutations in two genes (GJB2 or OTOF) in children up to 10 years of age.

Description

The study aims to:

  • better describe the prevalence of cases of DFNB1A and DFNB9, including the type of mutations, and to assess the clinical course of the disease in children up to 10 years of age who have a moderate to profound deafness.
  • better understand the audiological and genetic characteristics of the participants with congenital versus evolutive DFNB1A and DFNB9 deafness.

Eligibility

Main Inclusion Criteria:

        Participants meeting all the following main inclusion criteria will be eligible to
        participate in the study:
          -  Aged ≤ 10 years on the date of signed informed consent;
          -  With a diagnosis of non-syndromic, bilateral, moderate to profound, sensorineural
             hearing loss (according to the American Speech Language-Hearing Association);
          -  With documented genotyping results showing mutation(s) in GJB2 or OTOF genes;
          -  Written informed consent as required by local regulations.
          -  Either without Cochlear Implant, or with unilateral or bilateral Cochlear Implant(s)
        Exclusion Criteria:
        Participants presenting with any of the following main exclusion criteria will not be
        included in the study
          -  Other type of deafness, such as unilateral deafness, persistent conductive deafness,
             malformation syndrome, syndromic deafness, known familial deafness linked to mutations
             in other genes than OTOF or GJB2;
          -  Documented genotyping results showing pathogenic mutation(s) in other gene(s) than
             GJB2 or OTOF genes in the tested panel;
          -  Unable and/or unwilling to comply with all the protocol requirements and/or study
             procedures.

Study details

Sensorineural Hearing Loss, Bilateral, AUNB1, DFNB1A, Congenital Deafness

NCT05402813

Sensorion

26 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.